The Inhibitor of Nuclear Factor Kappa B Kinase Subunit Beta pipeline drugs market research report outlays comprehensive information on the Inhibitor of Nuclear Factor Kappa B Kinase Subunit Beta targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Inhibitor of Nuclear Factor Kappa B Kinase Subunit Beta pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Oncology, Immunology, Genito Urinary System, and Infectious Disease which include the indications Oncology, Ovarian Cancer, Inflammation, Acute Renal Failure (ARF) (Acute Kidney Injury), and Sepsis. It also reviews key players involved in Inhibitor of Nuclear Factor Kappa B Kinase Subunit Beta targeted therapeutics development with respective active and dormant or discontinued products.
The Inhibitor of Nuclear Factor Kappa B Kinase Subunit Beta pipeline targets constitutes close to six molecules. Out of which, approximately three molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase I, and Preclinical stages are 1, and 2 respectively. Similarly, the universities portfolio in Preclinical, and Discovery comprises 2, and 1 molecule.
Inhibitor of Nuclear Factor Kappa B Kinase Subunit Beta overview
Inhibitor of nuclear factor kappa-B kinase subunit beta is a protein encoded by the IKBKB gene. It plays an essential role in the NF-kappa-B signaling pathway which is activated by multiple stimuli such as inflammatory cytokines, bacterial or viral products, DNA damages or other cellular stresses. It acts as part of the canonical IKK complex in the conventional pathway of NF-kappa-B activation and phosphorylates inhibitors of NF-kappa-B on 2 critical serine residues. Free NF-kappa-B is translocated into the nucleus and activates the transcription of hundreds of genes involved in immune response, growth control, or protection against apoptosis.
For a complete picture of Inhibitor of Nuclear Factor Kappa B Kinase Subunit Beta’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
